Septerna (NASDAQ:SEPN) Trading Down 4.3% – Time to Sell?

Septerna, Inc. (NASDAQ:SEPN)’s share price traded down 4.3% on Wednesday . The company traded as low as $15.51 and last traded at $15.32. 23,687 shares traded hands during trading, a decline of 87% from the average session volume of 187,526 shares. The stock had previously closed at $16.01.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. TD Cowen assumed coverage on Septerna in a report on Tuesday, November 19th. They set a “buy” rating for the company. Cantor Fitzgerald started coverage on shares of Septerna in a research report on Tuesday, November 19th. They issued an “overweight” rating and a $50.00 price target on the stock. Wells Fargo & Company started coverage on shares of Septerna in a research report on Tuesday, November 19th. They issued an “overweight” rating and a $43.00 price target on the stock. Finally, JPMorgan Chase & Co. started coverage on shares of Septerna in a research report on Tuesday, November 19th. They issued an “overweight” rating and a $38.00 price target on the stock.

Septerna Trading Down 4.0 %

The firm has a 50-day moving average of $22.02.

Hedge Funds Weigh In On Septerna

A hedge fund recently bought a new stake in Septerna stock. SG Americas Securities LLC purchased a new position in Septerna, Inc. (NASDAQ:SEPN) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 8,095 shares of the company’s stock, valued at approximately $185,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.